ALX Oncology Holdings Inc is a clinical-stage biopharmaceutical company focused on novel immuno-oncology therapies with no approved products or revenue to date. Its lead candidates, evorpacept (ALX 148) and ALX2004, remain in early clinical phases, requiring significant ongoing investment amid a competitive landscape. The company has incurred substantial net losses each year, with operating income losses exceeding $100 million in 2025 and cash reserves supporting operations into early 2027 only. Dependency on future capital raises, regulatory approval outcomes, and competitive innovations constrain growth prospects. Watch for clinical trial readouts, milestone-driven funding opportunities, and capital management as key near-term corporate milestones.